Full-Time

Business Performance Manager

Updated on 8/17/2026

Deadline 9/30/26
Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's, Associate's

Category
Operations & Logistics (1)
Required Skills
Power BI
Agile
Python
Six Sigma
Data Visualization
SQL
Tableau
Risk Management
VBA
Data Analysis
Excel/Numbers/Sheets

Get referred to Amgen

See people who can refer or advise you

Requirements
  • Strong experience in process excellence, process improvement, process re-engineering, operational excellence, business transformation, business operations, or business performance management.
  • Demonstrated hands-on experience using data analysis, automation, dashboards, and reporting tools to solve business problems, measure performance, identify opportunities, and improve decision-making.
  • Experience with tools such as Excel, Power BI, Tableau, Smartsheet, Power Automate, Power Apps, VBA, SQL, Python, low-code/no-code platforms, workflow tools, or similar technologies.
  • Ability to work through ambiguity and create structure where processes, data, ownership, or success measures are not clearly defined.
  • Ability to work with imperfect data and develop pragmatic ways to generate insight, establish baselines, and measure improvement.
  • Strong project execution skills, including scope definition, work planning, stakeholder management, action tracking, issue resolution, benefits delivery, and closure discipline.
  • Ability to independently plan work, maintain momentum, follow through on commitments, and deliver outcomes with limited day-to-day direction.
  • Strong facilitation, communication, and influencing skills, including the ability to lead workshops, prepare leadership updates, and work effectively across functions and levels.
  • Strong attention to detail, documentation discipline, and ability to maintain accurate records, track follow-ups, and ensure timely completion of required activities.
  • Ability to combine a continuous improvement mindset with operational discipline, risk awareness, and readiness thinking.
  • Master's degree and 6 years of relevant experience, or Bachelor's degree and 8 years of relevant experience, or Associate's degree and 12 years of relevant experience.
Responsibilities
  • Lead and execute process excellence, automation, process re-engineering, and business performance improvement projects from opportunity identification through implementation and benefits realization.
  • Partner with site functions to assess current-state processes, identify pain points, map workflows, quantify inefficiencies, and design scalable future-state processes.
  • Apply Lean, Six Sigma, Kaizen, root cause analysis, value stream mapping, customer and employee journey mapping, and process mapping to solve business problems and deliver measurable outcomes.
  • Use data analysis, dashboards, reports, scorecards, and process metrics to diagnose issues, identify trends, establish baselines, monitor performance, and support leadership decision-making.
  • Establish practical data collection approaches, proxy measures, or simple measurement systems for fragmented, inconsistent, manual, incomplete, or unavailable data.
  • Identify and implement automation opportunities using relevant tools and platforms to reduce manual effort, improve data quality, increase process reliability, and enhance stakeholder experience.
  • Create structure in ambiguous problem spaces by clarifying objectives, identifying stakeholders, defining success measures, organizing available information, and building execution plans.
  • Facilitate workshops, stakeholder interviews, process design sessions, and problem-solving forums to align teams, make decisions, and drive action.
  • Support operational readiness for critical business processes through process mapping, dependency identification, role clarity, continuity and recovery documentation, readiness exercises, lessons learned, and action tracking.
  • Drive projects and improvement actions to closure through clear ownership, disciplined follow-through, stakeholder engagement, issue escalation, and benefits realization.
  • Build relationships with site leadership, functional stakeholders, global partners, and enabling teams to understand priorities and convert them into actionable improvement plans.
Desired Qualifications
  • Experience in biotechnology, pharmaceutical, healthcare, life sciences, global capability center, shared services, site operations, or regulated industry environments.
  • Experience leading end-to-end process improvement, automation, analytics, business transformation, or operational excellence projects with measurable outcomes.
  • Working knowledge of Lean, Six Sigma, Kaizen, value stream mapping, root cause analysis, process mining, workflow automation, or digital enablement methodologies.
  • Lean Six Sigma Green Belt, Project Management Professional, Agile, Business Analysis, Data Analytics, Automation, Operational Excellence, or related certification.
  • Hands-on experience with Power BI, Tableau, Smartsheet, Power Automate, Power Apps, Excel automation, SQL, Python, or similar analytics and automation tools.
  • Experience supporting operational readiness, business resilience, risk management, crisis readiness, business continuity planning, recovery planning, process mapping, dependency analysis, readiness exercises, lessons learned, or action tracking.
  • Ability to act as a practical, solutions-oriented partner to site and global stakeholders.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion; guidance increased to $38.2-$39.4 billion.
  • Repatha grew 37%, Evenity 38%, and Uplizna 90% in Q2 2026.
  • Colorado’s Enbrel price cap was blocked on July 1, 2026, preserving legacy cash flow.

What critics are saying

  • FDA proposed Tavneos withdrawal on April 27, 2026; a hearing loss kills ChemoCentryx economics.
  • Tavneos retraction and liver-injury findings threaten Amgen’s credibility with regulators and investigators in 2026.
  • Prolia erosion and patent battles, including Delaware’s June 2026 verdict, pressure margins until 2027.

What makes Amgen unique

  • MariTide’s monthly-to-quarterly dosing targets obesity convenience versus weekly GLP-1 rivals in 2027.
  • Amgen’s 2026 base is unusually diversified: Repatha, Evenity, Uplizna, Tezspire, and Imdelltra.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-linked discovery capacity globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.

PR Newswire
Aug 4th, 2026
Amgen reports 10% revenue growth to $10.1B in Q2 2026, driven by 26% surge in six key growth products

Amgen reported second quarter 2026 revenues of $10.1 billion, a 10% increase year-over-year. Product sales grew 9%, driven by volume growth across 22 products that achieved double-digit sales growth. The company's six key growth drivers grew 26% year-over-year, generating nearly 70% of second quarter product sales. GAAP earnings per share increased 65% to $4.37, whilst non-GAAP EPS rose 4% to $6.29. Notable product performance included Repatha sales increasing 37% to $953 million and EVENITY growing 38% to $714 million. The company generated $3.5 billion in free cash flow, compared to $1.9 billion in the prior year period. For full year 2026, Amgen expects total revenues between $38.2 billion and $39.4 billion, with non-GAAP EPS guidance of $22.30 to $23.50.